BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 31135527)

  • 1. Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Lulla PD; Mamonkin M; Brenner MK
    Cancer J; 2019; 25(3):199-207. PubMed ID: 31135527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy for acute myeloid leukemia.
    Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
    Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
    Boyiadzis M; Agha M; Redner RL; Sehgal A; Im A; Hou JZ; Farah R; Dorritie KA; Raptis A; Lim SH; Wang H; Lapteva N; Mei Z; Butterfield LH; Rooney CM; Whiteside TL
    Cytotherapy; 2017 Oct; 19(10):1225-1232. PubMed ID: 28864289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
    Lee JB; Chen B; Vasic D; Law AD; Zhang L
    Blood Rev; 2019 May; 35():18-31. PubMed ID: 30826141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will CAR T cell therapy have a role in AML? Promises and pitfalls.
    Cummins KD; Gill S
    Semin Hematol; 2019 Apr; 56(2):155-163. PubMed ID: 30926092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.
    Lemoli RM; Parisi S; Curti A
    Exp Hematol; 2017 Jan; 45():10-16. PubMed ID: 27826123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
    Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
    J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
    Gergis U; Frenet EM; Shore T; Mayer S; Phillips A; Hsu JM; Roboz G; Ritchie E; Scandura J; Lee S; Desai P; Samuel M; Ball J; Blanco A; Romeo C; Albano MS; Dobrila L; Scaradavou A; van Besien K
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):466-473. PubMed ID: 30414955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.
    Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V
    J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
    Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
    Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
    Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
    Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.
    Takahashi K; Wang F; Morita K; Yan Y; Hu P; Zhao P; Zhar AA; Wu CJ; Gumbs C; Little L; Tippen S; Thornton R; Coyle M; Mendoza M; Thompson E; Zhang J; DiNardo CD; Jain N; Ravandi F; Cortes JE; Garcia-Manero G; Kornblau S; Andreeff M; Jabbour E; Bueso-Ramos C; Takaori-Kondo A; Konopleva M; Patel K; Kantarjian H; Futreal PA
    Nat Commun; 2018 Jul; 9(1):2670. PubMed ID: 29991687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches.
    Ding G; Chen H
    Sci China Life Sci; 2016 Jul; 59(7):673-7. PubMed ID: 27142351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
    Bayón-Calderón F; Toribio ML; González-García S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches for the immunotherapy of acute myeloid leukemia.
    Geiger TL; Rubnitz JE
    Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.